Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
European operations' revenue grew 58.4% to Rs 599.7 crore
Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Glenmark will receive from Cassiopea, a subsidiary of Cosmo, the exclusive right to commercialize Winlevi in 15 EU countries
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
The company has entered into a three-year Deferred Prosecution Agreement
Subscribe To Our Newsletter & Stay Updated
